Navigation Links
LA Career Coach Unveils LifeStage Methodology to Help Individuals Make Effective Work-Life Choices
Date:3/24/2008

LOS ANGELES, March 24 /PRNewswire/ -- Whether you're facing a new beginning in your work, hitting career roadblocks, or encountering other challenges in making effective work-life decisions, the new LifeStage Methodology -- unveiled today by Daisy Swan, MA, CPCC: The Los Angeles Career Counselor & Coach -- can help you proactively address issues and goals you want to tackle.

Swan's re-launched website, http://www.daisyswan.com, features details on the LifeStage Methodology, plus new offerings to help individuals develop satisfying career/life strategies, even during this time of economic uncertainty.

"After 15-plus years as a career strategist, I developed this LifeStage Methodology to further assist my clients in attaining a fulfilling and satisfying working life," said Swan, a certified professional co-active coach through the Coaches Training Institute. "The methodology uses solution-oriented tools and strategies to assist individuals based on their current situation."

The LifeStage Methodology clarifies:

-- Beginning: When you have 0-8 years of work experience and want to

launch an effective work life.

-- Roadblock: When you've been moving in a direction with particular

outcomes in mind and realize you aren't achieving your expectations;

or when a major life change like becoming a parent, being laid off or

getting a divorce alters your path.

-- Authenticity: When you feel a new call to action requiring clarity

about what's important and essential now.

-- Wisdom: When you recognize it's time to make a difference while you

still can, and a new sense of urgency and purpose emerges for the

coming years.

Swan also announced new upcoming seminars and courses (all on the

Westside):

-- Navigating Career Change, April 3, 6:30-8:30 p.m.: This seminar will

off
'/>"/>

SOURCE Daisy Swan & Associates
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Bullying threatens nurses health and careers
2. Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years
3. Ben Barber Career Tech Academy Leaps Forward With Help From Methodist Mansfield
4. HEALTHeCAREERS Network Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
5. Looking for a Career? A New Study Shows Demand for Doctors of Podiatric Medicine to Surge Over the Next Six Years
6. Dorsey Schools, Detroit Areas Preeminent Career Training School, Opens a Fifth Campus in Farmington Hills
7. Students Pursuing Health Care Careers Receive $24,000 in Scholarships From National Hispanic Health Foundation
8. U.S. Career Institute Launches 1st Ever DETC Accredited Medical Assistant Course
9. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
10. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
11. DeviceSpace Career Fair Opens Doors for Hundreds of Medical Device and Diagnostics Career Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10